Uveal melanoma represents a rare and aggressive subtype of melanoma with limited
treatment options and poor prognosis, especially in the metastatic setting. Tebentafusp, a …

Simple Summary Multiple myeloma (MM) is a blood cancer which classically has a
prolonged course of remissions and relapses. Several new highly efficacious medications …

Patients with multiple myeloma (MM) were among the groups impacted more severely by the
COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality …

Multiple Myeloma (MM) prognosis has recently improved thanks to the incorporation of new
therapies to the clinic. Nonetheless, it is still a non-curable malignancy. Targeting cancer …

Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as
promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific …

The therapeutic management of patients with multiple myeloma (MM) is complex. Despite
substantial advances, MM remains incurable, and management involves cycles of treatment …

In this issue of Blood Advances, Long et al 1 describe a novel mouse model with humanized
CD3 that makes it ideal for studying bispecific antibodies (BsAbs). The authors provide proof …

MP0250 is a designed ankyrin repeat protein that specifically inhibits both vascular
endothelial growth factor A (VEGF‐A) and hepatocyte growth factor (HGF), aiming at …

Background Patient susceptibility to cytokine release syndrome (CRS) resulting from
immune‐modulating chemotherapy has profound implications for clinical outcome. This is …

Classical hairy-cell leukemia (chCL) is a rare chronic B-cell leukemia, more frequent in
middle-aged males [1, 2]. the diagnosis is based on bone marrow examination which …